Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat

Neuroscience

Volumn 215, Issue , 2012, Pages 149-159

  Akopian, G ^a   Crawford, C ^c   Petzinger, G ^a,b   Jakowec, M W ^a,b   Walsh, J P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

3 NP; Dopamine; LTD; LTP; Striatum

Indexed keywords

3 NITROPROPIONIC ACID; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; LOCOMOTION; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MALE; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SYNAPSE; SYNAPTIC INHIBITION;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; BENZAZEPINES; BIOPHYSICS; CEREBRAL CORTEX; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; FUNCTIONAL LATERALITY; MOVEMENT; NITRO COMPOUNDS; OXIDOPAMINE; PROPIONIC ACIDS; PROTEIN BINDING; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA; SULPIRIDE; SYNAPSES; TIME FACTORS; TRITIUM; TYROSINE 3-MONOOXYGENASE;

EID: 84861791982     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.04.060     Document Type: Article

References (80)

1. Akopian G., Crawford C., Beal M.F., Cappelletti M., Jakowec M.W., Petzinger G., Gheorghe S.L., Chow R., Walsh J.P. Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 hours after 3-nitropropionic acid induced chemical hypoxia. J Neurosci 2008, 28:9585-9597.
2. Akopian G., Walsh J.P. Reduced expression of short- and long-term facilitation at aged corticostriatal synapses. Synapse 2006, 60:223-238.
3. Alexi T., Hughes P.E., Knüsel B., Tobin A.J. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Exp Neurol 1998, 153:74-93.
4. Andre V.M., Cepeda C., Levine M.S. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010, 16:163-178.
5. Aspey B.S., Cohen S., Patel Y., Terruli M., Harrison M.J. Middle cerebral artery occlusion in the rat: consistent protocol for a model of stroke. Neuropathol Appl Neurobiol 1998, 24:487-497.
6. Aspey B.S., Taylor F.L., Terruli M., Harrison M.J. Temporary middle cerebral artery occlusion in the rat: consistent protocol for a model of stroke and reperfusion. Neuropathol Appl Neurobiol 2000, 26:232-242.
7. Beal M.F., Brouillet E., Jenknins B.G., Ferrante R.J., Kowal N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993, 13:4181-4192.
8. Bizat N., Hermel J.-M., Boyer F., Jacquard C., Créminon C., Ouary S., Escartin C., Hantraye P., Krajewski S., Brouille E. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J Neurosci 2003, 23:5020-5030.
9. Borlongan C.V., Koutouzis T.K., Freeman T.B., Cahill D.W., Sanberg P.R. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res 1995, 697:254-257.
10. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005, 95:1521-1540.
11. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., Roy D.S., Rosen B.R., Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993, 60:356-359.
12. Brustovetsky N., Brustovetsky T., Purl K.J., Capano M., Crompton M., Dubinsky J.M. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci 2003, 23:4858-4867.
13. Calabresi P., Gubellin P., Picconi B., Centonzone D., Pisan A., Bonsi P., Greengard P., Hipskind R.A., Borrelli R.A., Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 2001, 21:5110-5120.
14. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007, 30:211-219.
15. Calabresi P., Saiardi A., Pisani A., Baik J.-H., Centonze D., Mercur N.B., Bernardi G., Borrelli E. Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci 1997, 17:4536-4544.
16. Centonze D., Prosperetti C., Barone I., Ross S., Picconi P., Tscherter A., De Chiara V., Bernardi G., Calabresi P. NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. Exp Neurol 2006, 202:470-479.
17. Crawford C., Akopian G., Ring J., Jakowec M.J., Petzinger G.M., Andersen J.K., Vittozzi-Wong P., Wang K., Farley C., Charntikov S., Mitroi D., Chow R., Walsh J.P. Acute response and long-term adaptation of dopaminergic nigrostriatal synapses to a brief exposure to the complex II inhibitor 3-nitropropionic acid. Synapse 2011, 65:339-350.
18. Cull-Candy S., Brickleym S., Farrant M. NMDA receptor subunits: diversity, development, and disease. Curr Opin Neurobiol 2001, 11:327-335.
19. Dalbem A., Silveira C.V., Pedroso M.F., Breda R.V., Werne Baes C.V., Bartmann A.P., da Costa J.C. Altered distribution of striatal activity dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease. Brain Res 2005, 1047:148-158.
20. Dharker S.R., Mitta R.S., Bhargava N.M. Ischemic lesions in basal ganglia in children after minor head injury. Neurosurgery 1993, 33:863-865.
21. Dunia R., Buckwalter G., DeFazio T., Villa F.A.S., McNeill T.H., Walsh J.P. Decreased duration of calcium potentials in striatal neurons from aged rats. J Neurophysiol 1996, 76:2353-2363.
22. Fernagut P.O., Diguet E., Stefanova N., Biran M., Wenning G.K., Canioni P., Bioulac B., Tison F. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neurosci 2002, 114:1005-1017.
23. Friedmann M.N., Gerhardt G.A. Regional effects of aging on DA function in the Fischer-344 rat. Neurobiol Aging 1992, 13:325-332.
24. Garcia M., Vanhoutte P., Pages C., Besson M.-J., Brouillet E., Caboche J. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. J Neurosci 2002, 22:2174-2184.
25. Hagemann G., Redecker C., Neumann-Haefelin T., Freund H.J., Witte O.W. Increased long-term potentiation in the surround of experimentally induced focal cortical infarction. Ann Neurol 1998, 44:255-258.
26. Hamilton B.F., Gould D.H. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta Neuropathol 1987, 72:286-297.
27. Hankey G.J., Spiesser J., Hakimi Z., Carita P., Gabriel S. Time frame and predictors of recovery from disability following recurrent ischemic stroke. Neurology 2007, 68:202-205.
28. Hasbani M.J., Underhill S.M., Erausquin G., Goldberg M.P. Synapse loss and regeneration: a mechanism for functional decline and recovery after cerebral ischemia? the neuroscientist 2000, 6:110-119.
29. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. PNAS 1996, 93:1956-1961.
30. Hawker K., Lang A.E. Hypoxic-ischemic damage of the basal ganglia. Case reports and a review of the literature. Mov Disord 1990, 5:219-224.
31. Hazzard D.G., Bronson R.T., McClearn G.E., Strong R. Selection of an appropriate animal model to study aging processes with special emphasis on the use of rat strains. J Gerontol Bio Sci 1992, 47:B63-B64.
32. He F., Zhang S., Qian F., Zhang C. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid). Neurology 1995, 45:2178-2218.
33. Heim C., Arzberger T., Sontag T., Xiao A., Herbinger K.-H., Weindl A., Sontag K.-H. Progressive degeneration of dopamine system functions after transient cerebral oligemia in rats. Brain Res 1999, 851:235-246.
34. Huang L.-S., Sun G., Cobessi D., Wang A.C., Shen J.T., Tung E.Y., Anderson V.E., Berry E.A. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem 2006, 281:5965-5972.
35. Humm J.L., Kozlowski D.A., Bland S.T., James D.C., Schallert T. Use-dependent exaggeration of brain injury: is glutamate involved?. Exp Neurol 1999, 157:349-358.
36. Jana S., Maiti A.K., Bagh M.B., Banerjee K., Das A., Roy A., Chakrabarti S. Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease. Brain Res 2007, 1139:195-200.
37. Jenkins B.G., Brouillet W., Chen Y.-CI., Storey E., Schulz J.B., Kirschner P., Bea M.F., Rosen B.R. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996, 16:450-461.
38. Johnson J.R., Robinson B.L., Ali S.F., Binienda Z. Dopamine toxicity following long term exposure to low doses of 3-nitropropionic acid (3-NPA) in rats. Toxicol Lett 2000, 116:113-118.
39. Johnston M.V., Hoon A.H.Jr. Possible mechanisms in infants for selective basal ganglia damage from asphyxia, kernicterus, or mitochondrial encephalopathies. J Child Neurol 2000, 15:588-591.
40. Jones T.A., Schallert T. Overgrowth and pruning of dendrites in adult rats recovering from neocortical damage. Behav Brain Res 1992, 51:156-160.
41. Karanian D.A., Baude A.S., Brown Q.B., Parsons C.G., Bahr B.A. 3-nitropropionic acid toxicity in hippocampus: protection through N-methyl-d-aspartate receptor antagonism. Hippocampus 2006, 16:834-842.
42. Kerr J.N.D., Wickens J.R. Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J Neurophysiol 2001, 85:117-124.
43. Kim G.K., Copin J.-C., Kawase M., Chen S.F., Sato S., Gobbel G.T., Chan P.H. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J Cerebral Blood Flow Metab 2000, 20:119-129.
44. Koutouzis T.K., Borlongan C.V., Scorcia T., Creese I., Cahill D.W., Freeman T.B., Sanberg P.R. Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Res 1994, 646:242-246.
45. Kreitzer A.C., Malenka R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 2005, 25:10537-10545.
46. Kumar R., Nguyen H.D., Ogren J.A., Macey P.M., Thompson P.M., Fonarow G.C., Hamilton M.A., Harper R.M., Woo M.A. Global and regional putamen volume loss in patients with heart failure. Eur J Heart Fail 2011, 13:651-655.
47. Li L., Murphy T.H., Hayden M.R., Raymond L.A. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol 2004, 92:2738-2746.
48. Liot G., Bossy B., Lubitz S., Kushnareva Y., Sejbuk N., Bossy-Wetzel E. Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Different 2009, 16:899-909.
49. Lipman R.D., Chrisp C.E., Hazzard D.G., Bronson R.T. Pathologic characterization of Brown Norway, Brown Norway X Fischer 344, and Fischer 344 x Brown Norway rats with relation to age. J Gerontol Biol Sci 1996, 51:B54-B59.
50. Lynch D.R., Guttmann R.P. Excitotoxicity: perspectives based on N-methyl-d-aspartate receptor subtypes. J Pharmacol Exp Ther 2002, 300:717-723.
51. Martella G., Tassone A., Sciamanna G., Platania P., Cuomo D., Viscomi M.T., Bonsi P., Cacci E., Biagioni S., Usiello A., Bernardi G., Sharma N., Standaert D.G., Pisani A. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 2009, 132:2336-2349.
52. Masoro E.J. Animal models in aging research. The handbook of the biology of aging 1990, Academic Press, San Diego, CA. 3rd ed. E.L. Schneider, J.W. Rowe (Eds.).
53. Mirandola S.R., Melo D.R., Saito A., Castilho R.F. 3-Nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions. J Neurosci Res 2010, 88:630-639.
54. Mlynash M., Campbell D.M., Leprous E.M., Fischbein N.J., Bammer R., Eyngorn I., Hsia A.W., Moseley M., Wijman C.A.C. Temporal and spatial profile of brain diffusion-weighted MRI after cardiac arrest. Stroke 2010, 41:1665-1672.
55. Murphy T.H., Corbett D. Plasticity during stroke recovery: from synapse to behavior. Nat Rev Neurosci 2009, 10:861-872.
56. Nasr P., Carbery T., Geddes J.W. N-methyl-d-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity. Neurochem Res 2009, 34:490-498.
57. Nishimura M., Okimura Y., Fujita H., Yano H., Lee J., Suzaki E., Inoue M., Utsumi K., Sasaki J. Mechanism of 3-nitropropionic acid-induced membrane permeability transition of isolated mitochondria and its suppression by L-carnitine. Cell Biochem Funct 2008, 26:881-891.
58. Ou X., Buckwalte G., McNeill T.H., Walsh J.P. Age-related changes in short-term synaptic plasticity intrinsic to excitatory striatal synapses of the rat. Synapse 1997, 27:57-68.
59. Ou X., Walsh J.P. Aging decreases rebound excitation produced by removal of NMDA receptor block in the striatum. Exp Brain Res 1997, 114:590-594.
60. Ouary S., Bizat N., Altairac S., Menetra H., Mittoux V., Conde F., Hantraye P., Brouillet E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: Implications for neuroprotection studies. Neurosci 2000, 97:521-530.
61. Quinton M.S., Yamamoto B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006, 8:E337-E347.
62. Pandey M., Borah A., Varghese M., Barman P.K., Mohanakumar K.P., Usha R. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochem Int 2009, 55:431-437.
63. Pang Z., Geddes J.W. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J Neurosci 1997, 17:3064-3073.
64. Partridge J.G., Tang K.-C., Lovinger D.M. Regional and postnatal heterogeneity of activity-dependent long-term changes in synaptic efficacy in the dorsal striatum. J Neurophysiol 2000, 84:1422-1429.
65. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, New York.
66. Puerta E., Hervias I., Barros-Miñones L., Jordan J., Ricobaraza S., Cuadrado-Tejedo M., García-Osta A., Aguirre N. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Disease 2010, 38:237-245.
67. Sas K., Pardutz A., Toldi J., Vecsei L. Dementia, stroke and migraine-some common pathological mechanisms. J Neurol Sci 2010, 299:55-65.
68. Siviy S.M., Crawford C.A., Akopian G., Walsh J.P. Dysfunctional play and dopamine physiology in the Fischer 344 rat. Behav Brain Res 2011, 220:294-304.
69. Smith R., Musleh W., Akopian W., Buckwalter G., Walsh J.P. Regional differences in the expression of corticostriatal synaptic plasticity. Neuroscience 2001, 106:95-101.
70. Sonkusara S.K., Kaul C.L., Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005, 51:1-17.
71. VanLeeuwen J., Petzinger G.M., Vuckovic M., Akopian G., Ramirez M., Walsh J.P., Jakowec M.W. Altered AMPA-receptor expression with treadmill exercise in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci Res 2010, 88:650-668.
72. Villa F.A.S., Walsh J.P. Modulation of long-term synaptic plasticity at corticostriatal synapses. Neuroscience 1999, 90:1031-1041.
73. Villarán R.F., Tomás-Camardiel M., de Pablos R.M., Santiago M., Herrera A.J., Navarro A., Machado A., Cano J. Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. Neurotoxicology 2008, 29:244-258.
74. Wajner M., Goodman S.I. Disruption of mitochondrial homeostasis in organic acidurias: insights from human and animal studies. J Bioenerg Biomembr 2011, 43:31-38.
75. Wang Z., Kai L., Day M., Ronesi J., Yin H.H., Ding J., Tkatch T., Lovinger D.M., Surmeier D.J. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006, 50:443-452.
76. Ward N.S. Mechanisms underlying recovery of motor function after Stroke. Postgrad Med J 2005, 81:510-514.
77. Wallace B.A., Ashkan K., Heise C.E., Foote K.D., Torres N., Mitrofanis J., Benabid A.l. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007, 130:2129-2145.
78. Weindruch R., Masoro E.J. Concerns about rodent models for aging research. J Cienmtol: Biol Sci 1991, 46:B87-B88.
79. Wullner U., Young A.B., Penney J.B., Beal M.F. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 1994, 63:1772-1781.
80. Young A., Fagg Ge Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol Sci 1990, 11:126-133.